Samsung Biologics Total Debt vs. Shares Outstanding
| 207940 Stock | 934,000 2,000 0.21% |
For Samsung Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Samsung Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Samsung Biologics Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Samsung Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Samsung Biologics Co over time as well as its relative position and ranking within its peers.
Samsung |
Samsung Biologics Shares Outstanding vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Samsung Biologics's current stock value. Our valuation model uses many indicators to compare Samsung Biologics value to that of its competitors to determine the firm's financial worth. Samsung Biologics Co is rated second in total debt category among its peers. It is rated fourth in shares outstanding category among its peers . The ratio of Total Debt to Shares Outstanding for Samsung Biologics Co is about 15,661 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Samsung Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Samsung Biologics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Samsung Total Debt vs. Competition
Samsung Biologics Co is rated second in total debt category among its peers. Total debt of Biotechnology industry is presently estimated at about 2.29 Trillion. Samsung Biologics totals roughly 1.11 Trillion in total debt claiming about 49% of stocks in Biotechnology industry.
Samsung Shares Outstanding vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Samsung Biologics |
| = | 1.11 T |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Samsung Biologics |
| = | 71.17 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Samsung Shares Outstanding Comparison
Samsung Biologics is rated third in shares outstanding category among its peers.
Samsung Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Samsung Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Samsung Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Samsung Biologics' important profitability drivers and their relationship over time.
Use Samsung Biologics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Samsung Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Samsung Biologics will appreciate offsetting losses from the drop in the long position's value.Samsung Biologics Pair Trading
Samsung Biologics Co Pair Trading Analysis
The ability to find closely correlated positions to Samsung Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Samsung Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Samsung Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Samsung Biologics Co to buy it.
The correlation of Samsung Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Samsung Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Samsung Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Samsung Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Samsung Biologics position
In addition to having Samsung Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Market Funds Thematic Idea Now
Money Market Funds
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Samsung Stock
To fully project Samsung Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Samsung Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Samsung Biologics' income statement, its balance sheet, and the statement of cash flows.